MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Wearable-based digital measures from the Verily Study Watch can detect concurrent symptomatic treatment effects in a subset of early-stage Parkinson’s disease ORCHESTRA trial participants

    B. Bloem, V. Hinson, L. Gaetano, E. Goikoetxea, K. Ray, F. Ambrosetti, V. Ticcinelli, M. Key Prato, A. Pethe, C. Serrano Amenos, J. Trzebinski, S. Warma, A. Khanna, Z. Ali (Nijmegen, Netherlands)

    Objective: To investigate the effect of concurrent symptomatic treatment (ST) on digital measures collected in ORCHESTRA (NCT04658186). Background: Minzasolmin is an oral small molecule that…
  • 2025 International Congress

    Proof-of-Concept Study Design Leveraging Digital Biomarkers to Enhance Statistical Power and Reduce Sample Size in PD Trials

    S. Hendrix, J. Christensen, S. Jackson, P. O'Keefe, K. Hendrix, S. Dheerendra, F. Nahab, S. Dickson (Millcreek, USA)

    Objective: Parkinson's disease clinical studies for disease modifying therapies face challenges of large sample size and long study duration due to subtle changes at early…
  • 2025 International Congress

    A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

    S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)

    Objective: The study evaluates the effectiveness of Combat PD, a mobile app designed to remotely deliver and monitor gamified aerobic exercise in promoting adherence and…
  • 2025 International Congress

    A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson’s Disease

    X. Wei, L. Chen, X. Hu, J. Guo, C. Liu, J. Wang (Shanghai, China)

    Objective: To investigate the effectiveness, safety and pharmacokinetics of WD-1603 carbidopa-levodopa controlled-release tablets in subjects with Parkinson's disease. Background: The development of drug products that…
  • 2025 International Congress

    A Systematic Site Selection Approach to Ensure Efficient and Diverse Participant Recruitment to a Large-Scale Multi-Arm, Multi-Stage Platform Trial for Parkinson’s

    G. Mills, M-L. Zeissler, O. Bandmann, R. Barker, J. Carpenter, S. Collins, J. Duffen, S. Gandhi, L. Houlden, C. Gonzalez-Robles, C. Mcalpine, K. Mcfarthing, C. Pugh, A. Schapira, A. Schrag, C. Shakeshaft, T. Foltynie, C. Carroll (London, United Kingdom)

    Objective: To select up to 40 delivery sites to successfully recruit and retain a participant population representative of people with Parkinson’s disease (PwP) in the…
  • 2025 International Congress

    Peripheral insulin resistance may predict exenatide treatment response in Parkinson’s disease

    N. Vijiaratnam, C. Girges, J. Dickson, C. Caroll, M. Silverdale, M. Hu, G. Duncan, K. Chaudhuri, S. Gandhi, D. Athauda, Y. Li, N. Greig, K. Chowdhury, T. Foltynie (London, United Kingdom)

    Objective: To explore if the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide could modify the course of Parkinson’s disease (PD) and if peripheral insulin resistance (IR) mightdifferentially impact on this. Background: Exenatide…
  • 2025 International Congress

    Targeting IGF2 Signaling for Immune Modulation of Microglia in Parkinson’s Disease

    T. Huerta, V. Urbina, C. Aguilera, P. Chana, R. Vidal (Santiago, Chile)

    Objective: We propose that IGF2 induces a distinct inflammatory phenotype in macrophages or microglia derived from Parkinson’s disease (PD) patients. Background: Microglia are the resident…
  • 2025 International Congress

    Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

    M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

    Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…
  • 2025 International Congress

    Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension

    R. Gologorsky, A. Zolin, H. Ooi, H. Sarva (New York, USA)

    Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…
  • 2025 International Congress

    Transcutaneous Vagus Nerve Stimulation for Gait and Motor Function in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of transcutaneous vagus nerve stimulation (tVNS) on gait, motor function, and freezing of gait (FOG) in patients with Parkinson’s disease…
  • « Previous Page
  • 1
  • …
  • 139
  • 140
  • 141
  • 142
  • 143
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley